Search Results - "Barron, Richard L."

Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states by Lyman, Gary H., MD, MPH, FRCP, Lalla, Anjana, MS, Barron, Richard L., MS, Dubois, Robert W., MD, PhD

“…Abstract Background: Prophylaxis with granulocyte colony-stimulating factor reduces the risk for febrile neutropenia (FN) in patients receiving…”
Get full text

Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer by Lyman, Gary H, Barron, Richard L, Natoli, Jaime L, Miller, Ross M

“…Abstract Randomized controlled trials (RCTs) have suggested a potential advantage of dose-dense chemotherapy in improving disease-free and overall survival in…”
Get full text

Validated prediction of imminent risk of fracture for older adults by Sheer, Richard L, Barron, Richard L, Sudharshan, Lavanya, Pasquale, Margaret K

“…To develop and validate predictive models for imminent fracture risk in a Medicare population. This retrospective administrative claims (Humana Research…”
Get full text

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices by Denduluri, Neelima, Patt, Debra A, Wang, Yunfei, Bhor, Menaka, Li, Xiaoyan, Favret, Anne M, Morrow, Phuong Khanh, Barron, Richard L, Asmar, Lina, Saravanan, Shanmugapriya, Li, Yanli, Garcia, Jacob, Lyman, Gary H

“…A wide variety of myelosuppressive chemotherapy regimens are used for the treatment of cancer in clinical practice. Neutropenic complications, such as febrile…”
Get more information

Predictors of imminent risk of fracture in Medicare-enrolled men and women by Yusuf, Akeem A., Hu, Yan, Chandler, David, Crittenden, Daria B., Barron, Richard L.

“…Summary Advancing age, female sex, recent prior fracture and falls, and specific comorbidities and medications contribute to imminent (within 1–2 years) risk…”
Get full text

Botulinum Toxin A Improves the Quality of Life of Patients with Neurogenic Urinary Incontinence by Schurch, Brigitte, Denys, Pierre, Kozma, Chris M, Reese, Pat Ray, Slaton, Terra, Barron, Richard L

“…Abstract Objective To evaluate the impact of botulinum toxin type A (BoNTA) on health-related quality of life in patients with neurogenic urinary incontinence…”
Get full text

A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia by Dulisse, Brian, Li, Xiaoyan, Gayle, Julie A, Barron, Richard L, Ernst, Frank R, Rothman, Kenneth J, Legg, Jason C, Kaye, James A

“…The objective of this study was to provide up-to-date estimates of the clinical and economic burden that occurs during inpatient treatment of cancer patients…”
Get more information

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy‐induced neutropenia by Weycker, Derek, Barron, Richard L.

Get full text

Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle by Li, Xiaoyan, Luthra, Rakesh, Morrow, Phuong K, Fisher, Maxine D, Reiner, Maureen, Barron, Richard L, Langeberg, Wendy J

“…Patients receiving myelosuppressive chemotherapy with certain comorbidities are at increased risk of febrile neutropenia. A comprehensive evaluation of febrile…”
Get full text

Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer by Griffiths, Robert I., Barron, Richard L., Gleeson, Michelle L., Danese, Mark D., O’Hagan, Anthony, Chia, Victoria M., Legg, Jason C., Lyman, Gary H.

“…Background : Granulocyte-colony stimulating factor (G-CSF) reduces the risk of severe neutropenia associated with chemotherapy, but its cost implications…”
Get full text

Anaphylaxis upon Switching Lipid-Containing Amphotericin B Formulations by Cronin, John E., Barron, Richard L.

Get full text

Comparative effectiveness of colony-stimulating factors in febrile neutropenia prophylaxis: how results are affected by research design by Henk, Henry J, Li, Xiaoyan, Becker, Laura K, Xu, Hairong, Gong, Qi, Deeter, Robert G, Barron, Richard L

“…To examine the impact of research design on results in two published comparative effectiveness studies. Guidelines for comparative effectiveness research have…”
Get full text

Impact of neutropenic complications on short-term disability in patients with cancer receiving chemotherapy by Song, Xue, Fowler, Robert, Ruiz, Kimberly, Hurley, Dana, Barron, Richard L

“…The study examined the impact of chemotherapy-induced neutropenic complications (CINC), defined as neutropenia with fever or infection, on short-term…”
Get more information

Risk of febrile neutropenia (FN) in cancer patients (pts) receiving myelosuppressive chemotherapy and pegfilgrastim prophylaxis (PEG-P): Does day of administration matter? by Weycker, Derek, Li, Xiaoyan, Barron, Richard L., Figueredo, Jacqueline, Hagiwara, May

“…Abstract only…”
Get full text

The Impact of Primary Prophylaxis with Granulocyte Colony-Stimulating Factors on Febrile Neutropenia during Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials by Wang, Li, Baser, Onur, Kutikova, Lucie, Page, John H, Barron, Richard L

“…Introduction Febrile neutropenia (FN) is a dose-limiting toxicity of myelosuppressive chemotherapy that has been associated with decreased chemotherapy…”
Get full text

Use of Chemotherapy and Same-Day Pegfilgrastim Prophylaxis in US Clinical Practice by Weycker, Derek, Wu, Hongsheng, Hagiwara, May, Li, Xiaoyan, Barron, Richard L

“…Background: Primary prophylaxis with pegfilgrastim has been shown to reduce the risk of febrile neutropenia, a life-threatening consequence of myelosuppressive…”
Get full text

Risk of chemotherapy-induced febrile neutropenia (FN) with early discontinuation of pegfilgrastim prophylaxis (PEG-P) in U.S. clinical practice by Weycker, Derek, Li, Xiaoyan, Barron, Richard L., Li, Yanli, Reiner, Maureen, Kartashov, Alex, Figueredo, Jacqueline, Garcia, Jacob

“…Abstract only…”
Get full text

Chemotherapy-induced febrile neutropenia (FN) and FN prevention strategies in cancer care in the U.S. Veterans Health Administration (VHA) by Barron, Richard L., Wang, Li, Baser, Onur, Langeberg, Wendy J., Dale, David C.

“…Abstract only 6608 Background: Chemo-induced FN can be a life-threatening adverse event requiring immediate hospitalization and is associated with increased…”
Get full text

Febrile neutropenia and mortality in patients with breast cancer, lung cancer, and non-Hodgkin lymphoma by Kawatkar, Aniket A, Chao, Chun, Chen, Wansu, Barron, Richard L., Xu, Hairong, Reiner, Maureen, Vogl, Florian D., Chandler, David

“…Abstract only…”
Get full text

Determining the Understandability and Acceptability of an Oral Mucositis Daily Questionnaire by Tomlinson, Deborah, Isitt, John J., Barron, Richard L., Doyle, John, Judd, Peter, Gassas, Adam, Naqvi, Ahmed, Sung, Lillian

“…Oral mucositis research in children receiving anticancer therapy has been impeded by the lack of an acceptable, appropriate assessment scale. Some scales…”
Get full text